# A Phase II Study of HS-10353 in Participants With Postpartum Depression

> **NCT05937867** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Postpartum Depression

## Interventions

- **DRUG:** HS-10353 Capsules 30 mg, Oral, QN for 14 days
- **DRUG:** HS-10353 Capsules 50 mg, Oral, QN for 14 days
- **DRUG:** HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.
- **DRUG:** HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days

## Key facts

- **NCT ID:** NCT05937867
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-31
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-10-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05937867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05937867, "A Phase II Study of HS-10353 in Participants With Postpartum Depression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05937867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*